The Top 5 Biosimilar Articles for the Week of September 26

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of September 26, 2022.

Number 5: Realigning definitions and policies across regulatory agencies and developing a better understanding of how different stakeholders approach biosimilars could help get more patients and providers on board with using biosimilars, according to panelists at the DIA Biosimilars Conference.

Number 4: Panelists at the DIA Biosimilars Conference discussed how biosimilars can help address health care disparities and why patient notification for switching to biosimilars must be handled with caution.

Number 3: In a review article discussing the role of biosimilars in neovascular retinal diseases, the authors concluded that biologics have significantly improved patient outcomes, noting that vascular endothelial growth factor inhibitors are now considered first-line treatments.

Number 2: The final part of a 4-part series assessed what payers should know about the US introduction of adalimumab biosimilars coming in 2023 as well as policy considerations they can implement to reap the benefits of biosimilar savings.

Number 1: Ivo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, chronicled how drug prices as a result of biosimilar competition has evolved over time and what factors may contribute the most to price erosion.

To read all of these articles and more, visit centerforbiosimilars.com.